Fig. 1: Kaplan Meier estimates of overall survival.

A Overall survival in first-line HMA vs. HMA/Ven. B Overall survival among AHSCT cohort based on upfront therapy. C Overall survival in HMA/Ven in relapsed/refractory MDS after first-line HMA.